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Abstract.
Objective. The aim of this study was to identify the hepatitis C treatment intentions of Aboriginal people living with
hepatitis C virus (HCV) in Western Australia.
Methods. This study used a mixed-methods design. In the cross-sectional survey, 123 Aboriginal people who inject
drugs and self-report as living with hepatitis C completed a purpose-designed questionnaire. In the qualitative phase, 10
participants were interviewed about the factors influencing their future intentions to undertake hepatitis C treatment.
Results. Analysis of the survey data revealed significant associations between an intention to undertake hepatitis C
treatment and support, community attachment, stable housing and stigma. In addition, there was a high overall level of
expressed intention to undertake HCV treatment, with 54% of participants responding positively. Analysis of the
qualitative data supported quantitative findings, revealing concerns about stigma, lack of social support and unstable
housing as factors affecting the intention to undertake hepatitis C treatment.
Conclusion. This mixed methods study with Aboriginal people living with self-reported HCV indicates interven-
tions focused on reducing stigma and unstable housing could positively affect hepatitis C treatment intentions. These
findings have implications for developing holistic programs to promote and support people on hepatitis C treatment.
What is known about the topic? Substantial knowledge gaps need to be resolved if HCVelimination amongAboriginal
Australians is to be achieved. Current research has prioritised non-Aboriginal communities.
What does this paper add? This study found that stigma and unstable housing require attention if Aboriginal
Australians are to obtain the full benefits of direct acting antiviral (DAA) hepatitis C treatment.
What are the implications for practitioners? Reducing stigma (in the primary healthcare setting) and providing access
to stable housing are vital components of supportive, non-judgemental and culturally appropriate care for Aboriginal
people. This study highlights the importance of education for nurses and other primary care providers to increase
engagement in the hepatitis cascade of care. To achieve this, scaling-up of HCV treatment engagement, trainedAboriginal
community healthcare workers and HCV treatment advocates must mobilise and support Aboriginal people to avoid the
negative effects of stigma, build positive and enabling relationships and reinforce positive attitudes towards DAAhepatitis
C treatment.
Additional keywords: injecting drug use.
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HEALTH CARE FOR PEOPLE EXPERIENCING DISADVANTAGE
Introduction
Globally, peoplewho inject drugs are the predominant population
affected by hepatitis C virus (HCV).1 Recent Australian data
show a 15% increase in the notification rate of hepatitis C diag-
noses among the Aboriginal and Torres Strait Islander population
(from 138 per 100 000 population in 2012 to 173 per 100 000
population in 2016). Over a similar period, the rate of hepatitis C
diagnoses in the non-Aboriginal population decreased by 12%
(from 43.6 per 100 000 population in 2013 to 38.4 per 100 000
population in 2017).2 There are several well-documented health
and socioeconomic issues that increase the health inequalities of
Aboriginal people compared with their non-Aboriginal counter-
parts.3 These issues could be associated with insufficient clinical
care and access to health promotion interventions coupled with
a lack of disease prevention services.4 In addition, poverty,
homelessness and mental health issues may be associated with a
higher prevalence of HCV among Aboriginal people compared
with non-Aboriginal people.5Cultural respect is a key element for
ensuring Aboriginal people receive effective primary care, and
this includes an understanding of the social determinants of
health, as well as how individuals communicate their health
needs, and developing services that are culturally responsive so as
to achieve the most optimal care outcomes.6
Australia has been at the forefront of HCV elimination
globally. In February 2016, the Australian government placed
direct-acting antivirals (DAAs) on the Pharmaceutical Benefits
Scheme (PBS) for anyone living with HCV.7 Increasing access
to these highly tolerable and effective medications has seen a
considerable increase in the rate of treatment uptake since their
introduction.7 Surveillance data from the Kirby Institute high-
lights the rapid increases in interferon-free treatment uptake
between 2015 and December 2018 (from 3430 people to over
70 000 people).8 According to the Australian Needle Syringe
Program Survey, 3.7% of Aboriginal people reported undergo-
ing HCV treatment in 2015.9 However, there are no current
published data on the progress towards HCV elimination among
Aboriginal people in the context of new DAA treatment.8 Thus,
factors that affect the intentions of Aboriginal people to under-
take HCV treatment need to be examined.8
Sentinel surveillance data with people attending needle and
syringe programs shows that HCV prevalence rates are higher for
Aboriginal peoplewho inject drugs,10withAboriginal andTorres
Strait Islander respondents being almost twice as likely to report
receptive needle and syringe sharing as non-Aboriginal respon-
dents.11 Recent data indicate that the longer a person has been
living with HCV, the greater the severity of liver disease and the
higher the likelihood of developing liver cancer and early death.12
Consequently, there is a need to address the high prevalence of
hepatitis C in Aboriginal people. The focus of the present study
was to identify factors affecting treatment intention among
Aboriginal people living with HCV, with the aim of informing
relevant interventions and targeted strategies to enable increased
treatment uptake for Aboriginal people living with HCV.
Methods
A cross-sectional survey and semistructured interviews were
conducted between January and June 2015 in Western Australia
(WA). Participants who self-identified as Aboriginal and were
livingwith hepatitis Cwere recruited from the peer-based services,
namely the Western Australian Substance Users Association
(WASUA) in Perth and Bunbury, HepatitisWA, the WA Aids
Council (WAAC) Needle Syringe Exchange Program (NSEP)
fixed site andWAACNSEPmobile van services, which operate in
eight locations in the Perth metropolitan area.
All participants in the present study self-identified as Aborigi-
nal, were current injecting drug users (defined as at least monthly
injecting over past 6 months), self-reported as having received an
HCVdiagnosis fromahealthcare professionalmore than6months
prior to the interview (confirmatory tests were not performed),
were HCV treatment naı̈ve and were currently living in WA.
Written informed consent was obtained from all participants.
The first phase of data collection for this project involved
semistructured face-to-face interviews with eligible participants
(n ¼ 10). Participants were recruited by using posters, which
were placed in selected settings where injecting drug users could
see them during routine visits. Potential participants contacted
one of the authors (AR) by telephone to ask further questions,
after which appointments for interviews were arranged with
eligible participants. The duration of the interviews ranged
between 30 and 45 min and the interviews were conducted (by
RA) onsite in the premises of the organisations involved.
The second phase of the study consisted of a survey. Survey
participants (n ¼ 123) were not required to have completed
Phase 1 of the study. Recruitment for the survey was undertaken
through the distribution of study posters and information sheets
at the venues listed above, and potential participants contacted
the author (AR) directly by telephone to determine eligibility
and to arrange a time to complete the questionnaire. Participants
completed the questionnaire in a private room at the recruitment
site or in the WAAC mobile van.
Ethics approval for the study was received from Curtin
University (Reference no. 12/198) and the Fremantle Hospital
Human Research Ethics Committee (HR 77/2012). All partici-
pants were reimbursed for their time and effort with a supermar-
ket voucher to the value of an A$35 (qualitative arm) and A$20
(survey).
Study instrument
The survey instrument was adapted from previous Australian
studies and included questions regarding sociodemographics
and drug history,13 length of time since diagnosis,14 feeling a
part of the HCV-positive community,15 perceived HCV dis-
crimination and perceived stigma around disclosure,16 social
support,17 lifestyle changes18 and any intention to start treatment
in the next 5 years.19
Feeling a part of HCV-positive community
To establish participants’ feelings about community attach-
ment, they were asked 12 questions, including sources of help
seeking for the management of HCV, emotional support from
community-based organisations, the need for HCV services and
information about HCV treatment.
Perceived HCV discrimination and stigma
The scale used to establish perceptions of HCV discrimina-
tion and stigma16 consisted of 18 items; nine items measured
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perceived HCV discrimination and nine items examined per-
ceived stigma around disclosing HCV status.
Lifestyle since HCV diagnosis
Participants were askedwhether any changes in their lifestyle
had occurred since their HCV diagnosis. The scale used con-
sisted of five items: changes in diet, reduction or abstinence from
alcohol, increased exercise, HCV check-ups and any use of
complementary medicines.18
Social support
The scale used to assess social support17 contained 12 items,
which measured the level of support from family and friend(s),
as well as from healthcare providers if the participant had chosen
to undertake HCV treatment.
Treatment intention
Participants were asked whether they intended to undertake
treatment on four levels: in the next 12 months; in the next 1–2
years; in the next 2–5 years; or not for at least another 5 years.19
Responses from the Likert scale were transformed into dichot-
omous variables, namely ‘Disagree’ (grouping together the first
three responses, Strongly Disagree, Disagree, and Neutral) and
‘Agree’ (the last two responses, Agree and Strongly Agree); the
response ‘Neutral’ was included in the first group. This scoring
system was adopted from previous Australian studies5,20,21
that measured HCV treatment intention and suggested that ‘Neu-
tral’ did not necessarily mean ‘Agree’. ‘Disagree’ and ‘Agree’
were recategorised into ‘No’ and ‘Yes’ respectively. Median age
was used as a cut-off point to convert age into a binary variable.22
Heroin or amphetamine were the only drug choices available in
the survey; the duration of injecting drug use was dichotomised
into ‘8–10 years’ or ‘more than 11 years’ and the frequency of
injection reported as either ‘once a day’ or ‘more than once a day’.
Data analysis
Interview data were transcribed verbatim in Microsoft
(Redmond, WA, USA) Word and then uploaded into NVivo 10
(QSR International, Melbourne, Vic., Australia) to identify and
organise participants’ interview narratives. One of the authors
(AR) performed initial and axial coding to organise and review
the data, and then placed them into codes in order to find con-
nections between data. Coded data were read repeatedly for
emerging themes and analysed by one author (AR). A second
author (PH) reviewed the data and refined the coding with fur-
ther discussion until consensus was reached.
Data from the questionnaires were coded and entered into
SPSS version 22 (IBM Corp., Armonk, NY, USA). Descriptive
analysis was used to describe the characteristics of the sample.
Logistic regressionwas used to determine the predictors of HCV
treatment intention. In unadjusted analyses, variables at the
P , 0.10 level were considered for the multivariate model. In
the multivariate analysis, significant differences were assessed




More than two-thirds (n ¼ 7) of participants were men. Partici-
pants ranged in age from 34 to 48 years with a median age of
39.5 years. Half the participants reported stable accommodation,
with most living alone. All participants were unemployed and
reported their main source of income as government benefits
(Table 1). Three key themes were evident from the interviews,
namely stigma and shame, support and unstable housing. These
are outlined below and supported by narratives from participants.
Stigma and shame
Most participants (n ¼ 8) reported not publicly disclosing their
HCV status and linked their low intention to enter HCV treat-
ment to fear of exclusion from the community, their family and
the injecting drug use community. One participant described his
apprehension about HCV treatment as follows:
I’m too scared to go on HCV treatment, as I did not tell
anyone that I’m HCV positive, especially my parents and
especially my friends. I don’t want to reveal my HCV by
going on HCV treatment. It would be so embarrassing. I
didn’t want to be left out them and not feel attached to them. I
Table 1. Characteristics of participants in the qualitative study
(n5 10)










,Year 11 8 (80)




Living alone 8 (80)




Recent injecting drug use
Heroin 6 (60)
Methamphetamine 4 (40)




Once a day 5 (50)
More than once a day 5 (50)
Time since HCV diagnosis (years)
1–4 3 (30)
5–10 7 (70)
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believe it is a very common reason that has stopped people
going on HCV treatment. (Male, 38 years)
Participants believed that stigma remains central to the
experiences of being an injecting drug user living with HCV,
so enduring treatment with this stigma would expose them to
emotional distress:
Stigma is attached to HCV for a long time and going on HCV
treatment with this stigma attached to it is very difficult and it
hurts you emotionally and it could have an impact on your
mental health. (Male, 34 years)
Support
Few participants reported having family support and, without it,
they felt a lack of confidence to undertake HCV treatment.
Participants affirmed that a lack of support led them to not seek
HCV treatment due to loss of self-esteem, hope and self-efficacy.
For example, having a personal reminder to takeHCVmedication
on time during the HCV treatment course in case they missed
doses was seen as an important part of having treatment:
I have family here, but they are not helpful. They are drug
users tooyI have to manage everything on my own if I go on
HCV treatment, and keep thinking about who is gonna [sic]
remind me to take my medication on time if I go on HCV
treatment. I strongly believe that taking medication on
schedule and on time is really important to get the best result
out of treatment. I know myself that I am not good at these
things. Someone has to bewith you to remind you and keeping
you on the track until finishing treatment. So, how can I go
without having support frommy family?When you don’t have
support, it means you don’t have confidence and hope to be
fully committed to treatment. (Male, 43 years)
Some participants believed that the lack of a supportive
family stopped them from undergoing HCV treatment. They
believed that living with their family would enable them to
receive better care and support and, importantly, to follow the
treatment regime and commit to treatment completion:
I live on my own. I don’t have relationship with them, because
of my HCV, they try to stay away from me. So I can’t rely on
them at all. Living with family gives you luxury to feel relaxed,
comfortable, and importantly you don’t need to be worry
about forgetting or missing medication. When you can’t
communicate with your family, which means there is no help
and empathy, it makes you unwilling to take HCV treatment.
(Female, 39 years)
Unstable housing
Participants who were homeless (n ¼ 5) at interview described
this vulnerability as increasing the likelihood of them sharing
injecting equipment, exchanging sex for drugs and having
unprotected sex. They expressed frustration with their lack of
healthy food, inadequate sleep, difficulty storing HCV medi-
cations and a commitment to start the treatment journey. They
reported not having the resources to undertake HCV treatment
and that it did not make sense for them to do so while they lived
in such unstable environments. They perceived the ongoing
struggle of being homeless as a demotivating factor with regard
to HCV treatment:
You know, I’m homeless over the last two years. How can I go
on HCV treatment while I am homeless, how can I keep my
medication?How can I be on time for mymedicine? How can
I follow doctor instruction for taking my medicine? As a
homeless person, I do everything to earn money for my
expensesyso I can’t do it. When I am desperate for the
drugs and I don’t have a clean needle, I use other users’
needles. I don’t eat, sleep or shower properly. At the moment,
without a house, I just want to live and spend my life.
(Female, 40 years)
Homeless participants noted that they could not register
themselves with healthcare providers in order to commence
HCV treatment without a stable address and contact number.
Timely taking of medication was raised again and again as
important by participants:
I have been living on the streets for the past three years. As
you know, I need stable accommodationwith a stable address
and contact number to be able to enrol in HCV treatment. So
if I want to take HCV treatment, I need to go through a
registration process. How can I take my medicine on a
certain time, how can I be on track day by day until finishing
the treatment? At this stage, it is not possible. Having a stable
address is one of the key parts to go on HCV treatment.
(Male, 40 years)
Quantitative survey results
Over three-quarters of respondents were male (77.2%) and the
median age of participants was 38 years (Table 2). Almost one-
third (30%) described themselves as homeless and almost half
(44.7%) were from a non-metropolitan area. More than 80% of
participants were unemployed and received government bene-
fits. Participants identified either heroin or amphetamine as their
preferred drug, with almost 60%of participants reportingmostly
injecting heroin over the past 6months.All participants had been
injecting for longer than 8 years, with almost 60% injecting for
11 years or longer. Half the study participants reported being
diagnosed with HCV for between 1 and 4 years before the
interview, with a little over half (54%) indicating an intention to
undertake future HCV treatment.
Factors associated with intention to undertake HCV
treatment
In the bivariate analysis, most of the variables were significantly
associated with an intention to undertake HCV treatment. Only
the ‘living status’ variable was not significantly associated with
an intention to undertake HCV treatment. The factors that
remained significantly associated with intention to take up HCV
treatment after multivariate analysis included accommodation
status, support, perceived stigma and community attachment.
Participants who reported an intention to seek HCV treatment
were more likely to have social support (adjusted odds ratio
(aOR) 3; 95% confidence interval (CI) 1.1–8.1) and to have
stable accommodation (aOR6; 95%CI 1.01–38.87). In addition,
those participants who intended to take up treatment were more
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likely to interact with their Aboriginal community (aOR 5.1;
95% CI 1.12–23.76). However, those reporting no intention to
undergo treatment were more likely to perceive HCV stigma
(aOR 0.21; 95% CI 0.07–0.61; Table 3).
Discussion
Limited attention has been paid to the experiences of Australian
Aboriginal people living with HCV, particularly in WA.
A clinical and epidemiological study indicates that this popu-
lation is overrepresented in the HCV epidemic but historically
under-represented in HCV treatment.23 The quantitative data in
the present study indicate that approximately half the partici-
pants (54%) expressed an intention to undertake treatment in the
future. Brener et al. used a similar instrument to measure HCV
treatment intention in their study of 203Aboriginal people living
in New South Wales with HCV and found that 66% planned to
go treatment in the future.24 The high levels of HCV treatment
intention found in the study of Brener et al.24 is perhaps not
surprising given the imminent arrival of DAA treatment when
that studywas conducted. The higher efficacy of DAA treatment
and the fewer reported side-effects of DAAs than previous
interferon-based HCV treatments25 have made treatment a more
viable option.
The stigma associated with drug injecting and/or HCV has
been identified previously as a key reason for reduced intention
to engage with HCV treatment.24,26 Some participants in the
qualitative phase of the present study reported that they felt
healthcare services treated them differently from people with
other chronic diseases. They reported that these services did not
meet their needs or their expectations, and they assumed that the
substandard care they received was because of their status as
someone who was injecting drugs. Other studies have also
reported stigmatised individuals are less likely to have a health-
care consultation and are less likely to take up treatment.27,28
Even with the availability of DAA treatment, stigma needs to be
addressed among communities affected by HCV so the full
benefits can be obtained from DAA treatment.8
The present study is the first with Aboriginal people inWA to
find a relationship between community attachment and greater
intent to enter HCV treatment, reflecting the importance of
community attachment in undertaking HCV treatment. As indi-
cated by the data, those participants with a stronger sense of
attachment to an Aboriginal community had a higher intention to
take up HCV treatment. This suggests that a strong sense of
belonging to the communitymay act as a buffer against the stigma
of living with chronic illness by building positive relationships
within the community and fostering a positive outlook on
health.29 That is, community attachment increases the intention
to undertake treatment andmay be seen as protecting participants
against the negative effects of stigma, as well as encouraging and
supporting treatment engagement. This support may provide
opportunities that enable participants to obtain a deeper under-
standingofwhat is involved in treatment and treatment outcomes.
Hearing positive stories or seeing successful treatment outcomes
of DAA treatment from peers has been found to increase the
intention of First Nation Peoples to undertake HCV treatment in
other settings.30 Peer support can also play a significant role in
motivating and encouraging injecting drug users with HCV to
accomplish treatment.31–33 This may be true for Aboriginal
people with a strong network within their community, where
peer support can improve engagement and opportunities to
undertake HCV treatment.26
Lack of support was another main reason for treatment refusal
specified by the narratives of participants in the qualitative phase
of this study. The absence of social support has been identified as
a key factor for treatment refusal in similar studies with Aborigi-
nal and non-Aboriginal people.24 However, the quantitative data
indicated that 68% believed theywould have the necessary social
support if they undertook HCV treatment. A possible reason for
Table 2. Characteristics of participants in the quantitative study
(n5 123)










,Year 11 103 (83.7)





Living alone 48 (39)




Recent injecting drug use
Heroin 72 (58.5)
Methamphetamine 51 (41.5)




Once a day 40 (32.5)
More than once a day 83 (67.5)















Intention to undertake HCV treatment
No 56 (45.5)
Yes 67 (54.5)
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this discrepancy is that more people in the qualitative arm of the
study lived alone and reported family breakdown, and so lacked
strong and intimate relationships with their families. In addition,
the family members of some of the participants in the qualitative
phase were reported to be heavy drug users or to have other
chronic illnesses, further reducing the support available.
Unstable housing was identified as an important reason for
reporting no intention to seek HCV treatment. Homeless partici-
pants in the present study reported that they focused on the day-
to-day problems of living on the street, including lack of regular
sleep, physical exhaustion and daily anxiety. Some participants
reported they injected unsafely and that they consumed large
amounts of alcohol. It was difficult for them to follow medical
advice about following the strict schedule of daily medication.
This is confirmed by the quantitative analysis, which found that
stable accommodation was a significant predictor of a high
intention to undertake HCV treatment in both the univariate
and multivariate analyses. This is in line with other studies that
reported unstable housing to be associated with low intention to
take up HCV treatment.34
Table 3. Unadjusted and adjusted analyses of factors associated with hepatitis C virus (HCV) treatment intention
Unless indicated otherwise, data are given as n (%). aOR, adjusted odds ratio; CI, confident interval; OR, odds ratio
Characteristics Intention to take up HCV treatment OR (95% CI) P-value aOR (95% CI) P-value
Yes (n¼ 66; 54%) No (n¼ 57; 46%)
Sex
Male 38 (40) 57 (60)
Female 19 (68) 9 (32) 0.3 (0.12–0.77) 0.009
Age (years)
,38 39 (72.2) 15 (27.8)
38 18 (26) 51 (74) 7.36 (3.3–16.42) ,0.001
Accommodation
Homeless 33 (89) 4 (11)
Non-homeless 24 (28) 62 (72) 21.31 (6.81–66.61) ,0.001 6.28 (1.01–38.87) ,0.001
Education
,Year 11 43 (41.7) 60 (58.3)
Year 11 14 (70) 6 (30) 0.3 (0.1–0.86) 0.02
Employment status
Unemployed 52 (52) 48 (48)
Employed 5 (21.7) 18 (78.3) 3.9 (1.34–11.32) 0.009
Living status
Alone 25 (52) 23 (47.9)
Living with spouse or friends 41 (54.8) 34 (45.3) 1.1 (0.537–2.293) 0.779
Residency status
Non-metropolitan 34 (61.8) 21 (38.2)
Metropolitan 23 (33.8) 45 (66.2) 3.16 (1.51–6.64) 0.002
Recent injecting drug use
Heroin 43 (59.7) 29 (40.3)
Methamphetamine 14 (27.5) 37 (72.5) 3.91 (1.8–8.5) ,0.001
Duration of drug use (years)
8–10 19 (37.3) 32 (62.7)
11 38 (52.8) 34 (47.2) 0.53 (0.25–1.1) 0.089
Frequency of injecting
Once a day 14 (35) 26 (65)
More than once a day 43 (51.8) 40 (48.2) 0.5 (0.23–1.09) 0.08
Time since HCV diagnosis (years)
1–4 46 (61.3) 29 (38.7)
5–10 11 (23) 37 (77) 5.33 (2.35–12) ,0.001
Social support
No 36 (62) 22(38)
Yes 21 (32.3) 44 (67.7) 3.42 (1.63–7.2) ,0.001 3 (1.1–8.1) 0.02
Community attachment
No 41 (83.7) 8 (16.3)
Yes 16 (21.6) 58 (78.4) 18.57 (7.27–47.47) ,0.001 5.1 (1.12–23.76) 0.03
Perceived HCV stigma
No 13 (25) 39 (75) 0.2 (0.09–0.45) ,0.001 0.21 (0.07–0.61) ,0.001
Yes 44 (62) 27 (38)
Positive lifestyle change
No 37 (66) 19 (34) 4.57 (2.13–9.8) ,0.001
Yes 20 (30) 47 (70)
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As noted earlier, many clinicians advocate that for DAAs to be
effective, strict adherence is important; hence, unstable housing
may remain as a factor deterring homeless people from starting
their treatment. Recent evidence indicates that daily or weekly
dosing of DAAs can support and enhance adherence and optimise
treatment outcomes.35 Strategies such as extending DAA treat-
ment beyond the planned duration is one practicalwayof reducing
the effect of missing, forgetting or skipping doses.36 Other similar
strategies that provide support to build confidence and enable
people to attempt treatment are alsoworthy of attention. Concerns
remain that people experiencing homelessness lack awareness of
DAA treatment and are less likely to initiate treatment.37 There-
fore, further efforts are required to provide in-depth information of
DAAs to this population. One focusmay include peoplewho have
successfully completed DAA treatment and looking to them as
advocates through peer support, including telephone calls and/or
text messaging.
This study is limited by the absence of serological testing to
confirm self-reported HCV status, although previous Australian
studies demonstrate goodvalidity and reliabilitywith self-reported
data.38 In addition, there is the potential for social desirability bias,
because participants may have reported an intention to undertake
HCV treatment to avoid stigmatisation shame when talking to the
interviewer. Additional limitations include the cross-sectional
study design, which could only estimate the intention to undertake
treatment at one point in time, whereas participants’ intention to
undertake treatment may change over time, especially as DAA
treatments become more widely available.
Despite the increased availability of DAA treatment for
people living with HCV, data on the uptake of HCV treatment
among Aboriginal people remain limited. As noted above, the
implementation of effective strategies to extend DAA treatment
to Aboriginal people living with HCV must include culturally
appropriate and targeted interventions focused on maximising
treatment uptake among Aboriginal people. Further efforts are
required to promote locally focused health approaches that
improve the daily living conditions and make structural changes
that increase access to HCV treatment programs. Doing this,
together with trained Aboriginal community healthcare workers
and HCV treatment advocates, could help avoid stigmatisation
while at the same time supporting those more vulnerable,
including homeless, individuals. Such structural changes will
encourage engagement in HCV treatment, optimise treatment
outcomes and support broader HCV elimination goals.
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Ross RS, Bremer V, Marcus U, Zimmermann R, DRUCK Study Group.
Concordance between self-reported and measured HIV and hepatitis C
virus infection status among people who inject drugs in Germany.
Hepatol Med Policy 2016; 1: 8.
www.publish.csiro.au/journals/ahr
762 Australian Health Review A. Rashidi et al.
